A Case of Paradoxical Reactions to Biologic Therapy for Psoriasis

References

• Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JN. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi:10.1016/S0140-6736(20)32549-6
   PubMed Web of Science ®Google Scholar
• Miyagawa F. Pathogenesis of paradoxical reactions associated with targeted biologic agents for inflammatory skin diseases. Biomedicines. 2022;10(7):1485. doi:10.3390/biomedicines10071485
   PubMed Web of Science ®Google Scholar
• McKenzie F, Cash D, Gupta A, Cummings LW, Ortega-Loayza AG. Biologic and small-molecule medications in the management of pyoderma gangrenosum. J Dermatolog Treat. 2019;30(3):264–276. doi:10.1080/09546634.2018.1506083
   PubMed Web of Science ®Google Scholar
• Yamamoto T. An update on Adalimumab for pyoderma gangrenos. Drugs Today. 2021;57(9):535–542. doi:10.1358/dot.2021.57.9.3293619
   PubMed Web of Science ®Google Scholar
• Hellstrom AE, Farkkila M, Kolho KL. Infliximab-induced skin manifestations in patients with inflammatory bowel disease. Scand J Gastroenterol. 2016;51(5):563–571. doi:10.3109/00365521.2015.1125524
   PubMed Web of Science ®Google Scholar
• Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;164(1):10–22. doi:10.7326/M15-0729
   PubMed Web of Science ®Google Scholar
• Wlodarczyk M, Sobolewska A, Wojcik B, Loga K, Fichna J, Wisniewska-Jarosinska M. Correlations between skin lesions induced by anti-tumor necrosis factor-alpha and selected cytokines in Crohn’s disease patients. World J Gastroenterol. 2014;20(22):7019–7026. doi:10.3748/wjg.v20.i22.7019
   PubMed Web of Science ®Google Scholar
• Esmailzadeh A, Yousefi P, Farhi D, et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology. 2009;219(3):263–267. doi:10.1159/000235582
   PubMed Web of Science ®Google Scholar
• Davaine AC, Saraux A, Prigent S, et al. Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study. J Eur Acad Dermatol Venereol. 2008;22(12):1471–1477. doi:10.1111/j.1468-3083.2008.02935.x
   PubMed Web of Science ®Google Scholar
• Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update. Pharmacol Res. 2023;187:106552. doi:10.1016/j.phrs.2022.106552
   PubMed Web of Science ®Google Scholar
• Wollenberg A KM, Arents B, Aszodi N, et al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi:10.1111/jdv.18345
   PubMed Web of Science ®Google Scholar
• Maverakis E, Marzano AV, Le ST, et al. Pyoderma gangrenosum. Nat Rev Dis Primers. 2020;6(1). doi:10.1038/s41572-020-0213-x
   PubMed Web of Science ®Google Scholar
• Puig L. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. Curr Probl Dermatol. 2018;53:49–63.
   PubMedGoogle Scholar
• Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161(4):1118–1132. doi:10.1053/j.gastro.2021.07.042
   PubMed Web of Science ®Google Scholar
• Patel F, Fitzmaurice S, Duong C, et al. Effective strategies for the management of pyoderma gangrenosum: a comprehensive review. Acta Derm Venereol. 2015;95(5):525–531. doi:10.2340/00015555-2008
   PubMed Web of Science ®Google Scholar
• Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol. 2018;14(3):225–233. doi:10.1080/1744666X.2018.1438269
   PubMed Web of Science ®Google Scholar
• Margaret A, Fonder B, Deborah L, et al. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds. 2006;5(8):66–71.
   Google Scholar
• Jaimes-Lopez N, Molina V, Arroyave JE, et al. Development of pyoderma gangrenosum during therapy with infliximab. J Dermatol Case Rep. 2009;3(2):20–23. doi:10.3315/jdcr.2009.1027
   PubMedGoogle Scholar
• Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2018;29(1):13–18. doi:10.1080/09546634.2017.1329511
   PubMed Web of Science ®Google Scholar
• Lozano JF, Giménez RS, Fernández MC. Emergence of inflammatory bowel disease during treatment with secukinumab. J Crohns Colitis. 2018;12(9):1131–1133.
   PubMed Web of Science ®Google Scholar
• Fauny M, Moulin D, D’Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79(9):1132–1138. doi:10.1136/annrheumdis-2020-217927
   PubMed Web of Science ®Google Scholar
• Alavi A, French LE, Davis MD, Brassard A, Kirsner RS. Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2017;18(3):355–372. doi:10.1007/s40257-017-0251-7
   PubMed Web of Science ®Google Scholar
• Jin K, Matsuzaki Y, Akasaka E, Nakano H, Sawamura D. Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab. J Dermatol. 2019;46(3):e108–e109. doi:10.1111/1346-8138.14611
   PubMed Web of Science ®Google Scholar
• Petty AJ, Whitley MJ, Balaban A, Ellington K, Marano AL. Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab. JAAD Case Rep. 2020;6(8):731–733. doi:10.1016/j.jdcr.2020.06.011
   PubMedGoogle Scholar
• Nakamura M, Lee K, Singh R, et al. Eczema as an adverse effect of anti-TNFalpha therapy in psoriasis and other Th1-mediated diseases: a review. J Dermatol Treat. 2017;28(3):237–241. doi:10.1080/09546634.2016.1230173
   PubMed Web of Science ®Google Scholar
• Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007;156(3):486–491. doi:10.1111/j.1365-2133.2007.07682.x
   PubMed Web of Science ®Google Scholar
• Al‐Janabi A, Foulkes AC, Mason K, Smith CH, Griffiths CEM, Warren RB. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(7):1440–1448. doi:10.1111/jdv.16246
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266–1276. doi:10.1111/bjd.14403
   PubMed Web of Science ®Google Scholar
• Scheinberg M, Machado LA, Ferreira SB, Michalany N, Michalany N. Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. J Transl Autoimmun. 2021;4:100099. doi:10.1016/j.jtauto.2021.100099
   PubMedGoogle Scholar
• Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927–940. doi:10.1016/j.jaci.2021.08.009
   PubMed Web of Science ®Google Scholar
• Fieke M, Rosenberg LL, Marie LA. Baricitinib treatment of severe chronic hand eczema: two case reports. Contact Dermatitis. 2022;86(5):419–421. doi:10.1111/cod.14039
   PubMed Web of Science ®Google Scholar
• Allam JP, Novak N. The pathophysiology of atopic eczema. Clin Exp Dermatol. 2006;31(1):89–93. doi:10.1111/j.1365-2230.2005.01980.x
   PubMed Web of Science ®Google Scholar